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Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as
immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a
role in controlling cancer.
Methods: The percentage of dendritic cells and CD4+ and CD8+ T cells in the spleen (flow cytometry), cytokines’
release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from
tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 μg/kg of body weight. Statistical
analysis was performed by one-way ANOVA with Tukey’s post hoc test.
Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of
IFN-γ and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-β levels were decreased. There was also an increase in
macrophage’s activation, as denoted by the higher percentage of macrophages expressing adhesion and
costimulatory molecules (CD54 and CD80, respectively).
Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.
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Tumor cells are confronted with immune cells at each
stage of malignancy in the host, within the tumor, in the
blood and lymph circulation and in metastatic lesions
[1]. Cancer immunotherapy aims to stimulate the im-
mune system to destroy tumors, i.e. by enhancing the
production of cytokines and other immune mediators
that might act to eliminate the tumor cells.
Pulchellin is a type 2 ribosome-inactivating protein
(RIP) isolated from the seeds of Abrus pulchellus tenui-
florus. Type 2 RIPs, like ricin and abrin, are heterodi-
meric proteins composed of an enzymatic A-chain
covalently linked by a single disulfide bond to a B-chain.
The A-chain has the toxic rRNA-specific N-glycosidase* Correspondence: carlosiz@fcfar.unesp.br
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reproduction in any medium, provided the oractivity, and the B-chain has lectin activity towards spe-
cific carbohydrate moieties present on the surfaces of
mammalian cells. Pulchellin has an affinity for β-D-
galactose [2], a carbohydrate that is present on the sur-
face of many eukaryotic cells. This feature enables this
RIP to bind to glycoproteins and glycolipids on the cell
surface, after which it is internalized by different
mechanisms [3]. Several studies have reported the
mechanisms of pulchellin interaction with membrane
model systems [4] and the endocytosis machinery in K-
562 cells [2], but there have been no reports of the im-
munological activities of this protein.
In the present study, we investigated the immune re-
sponse in tumor-bearing mice treated with pulchellin. A
high production of IFN-γ was observed, possibly respon-
sible for the observed macrophage activation, including
nitric oxide and TNF-α production and an enhanced ex-
pression of adhesion and costimulatory molecules; the
increased production of the cytokines IL-10 and IL-4,
but decreased IL-6 and TGF-β production, was also
observed.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Materials
Native pulchellin was isolated [5] and kindly provided by
Dr. Ana Paula Ulian de Araújo from the Physics Insti-
tute of São Carlos – USP, Brazil.
Cell culture
The tumor cell line LM3, derived from a murine mam-
mary adenocarcinoma that spontaneously arose in BALB/
c mice, was kindly provided by Dr. Lucas L. Colombo
from Angel H. Roffo Institute, Buenos Aires, Argentina.
Cells were maintained in MEM medium (Gibco, BRL)
supplemented with 3 mM L-glutamine, 80 μg/ml genta-
mycin and 5% heat-inactivated fetal calf serum (FCS) at
37°C in a humidified 5% CO2 air atmosphere. Cells were
detached by the trypsinization (0.25% trypsin and 0.02%
EDTA, in Ca2+- and Mg2+-free PBS) of confluent mono-
layers. The medium was replaced three times per week.
Cell viability was assayed using a Trypan blue exclusion
test, and the absence of mycoplasma was confirmed by
the Hoechst method.
Animals
Female BALB/c mice (2-3-month-old) weighing around
20 g were purchased from the animal facility of UNI-
CAMP, São Paulo, Brazil. Sterilized water and food were
provided ad libitum. All animal procedures were per-
formed in accordance with the regulations of the
Research Ethics Committee (# 28/2008), Faculty of
Pharmaceutical Sciences, UNESP, São Paulo, Brazil.
Experimental groups
LM3 cells (1 × 106 cells) were injected subcutaneously in
the flanks of 2-3-month-old female BALB/c mice. After
20 days, LM3 tumor-bearing mice were injected intratu-
morally with 0.1 ml of pulchellin at 0.75 μg/kg of body
weight (10 times the in vitro IC50 concentration) (group
P) or phosphate buffered saline (group T). The mice in
group N did not receive treatment (healthy mice). The
mice were sacrificed after 7 days of treatment.
Peritoneal macrophages
Thioglycollate-elicited peritoneal exudate cells (PEC)
were harvested from group P, group T and group N mice
using 5.0 ml of sterile PBS, pH 7.4. The cells were
washed twice by centrifugation at 200 g for 5 min at 4°C
and resuspended in the appropriate medium for each
test.
Isolation of splenic lymphocytes
Spleens were resected from group P, group T and group
N mice under sterile conditions and macerated to pro-
duce single cell suspensions. After red blood cell lysis,
the cells were washed twice by centrifugation at 200 gfor 5 min at 4°C and resuspended in the appropriate
medium for each test.
Flow cytometry analysis
The cells were adjusted to a concentration of 1x106
cells/ml in PBS containing 1% BSA. Peritoneal exudate
cells were stained with the following fluorescent dye-
conjugated monoclonal antibodies (Mab) from BD
Biosciences: CD11b fluorescein isothiocyanate (FITC),
CD54 phycoerythrin (PE) and CD80 allophycocyanin
(APC). Spleen cells were stained with the following
fluorescent dye-conjugated monoclonal antibodies
(Mab), also from BD Biosciences: CD3 FITC, CD4 PE,
CD8a peridinin chlorophyll cyanine 5.5 (PerCP-Cy5.5),
CD11c FITC, CD25 APC, CD86 APC and I-Ad/I-Ed
(MHC II) PE. Corresponding IgG isotypes were used
as controls to account for non-specific binding (BD
Biosciences). Prior to cell staining, non-specific binding
sites were blocked with mouse BD Fc Block (BD Bios-
ciences). Cell surface markers were stained for 30 min
at 4°C, washed with staining buffer (PBS containing
1% BSA) and then fixed in 1% paraformaldehyde at
4°C until analysis. Flow cytometry data were acquired
using a FACSCanto instrument (BD Immunocytometry
System, USA) and analyzed using FACSDiva Software
(BD Biosciences).
Measurement of nitric oxide (NO) production
NO production was determined by assaying the nitrite
levels of the culture supernatants using the Griess
reagent. PEC (adherent cells) at 5x106 cells/ml in RPMI-
1640 medium supplemented with 2x10-5 M 2-mercap-
toethanol, 100 U/mL penicillin, 100 U/ml streptomycin,
2 mM L-glutamine and 5% FCS (complete RPMI) were
incubated for 24 h at 37°C in a 7.5% CO2 atmosphere.
Cell-free supernatant (50 μl) was mixed with 50 μl Griess
reagent (0.1% sulfanilamide, 3% phosphoric acid and 0.1%
naphthyl ethylenediamine) and incubated at room
temperature for 10 min in the dark. After incubation,
absorbance was read at 540 nm on a microplate reader
(Multiskan, Labsystems, Finland). The nitrite concen-
tration was calculated based on a standard curve. The
results were expressed in μmols/ml [6].
Measurement of cytokines production
The levels of IL-6 and TNF-α in the PEC culture super-
natants and IL-4, IL-10, IFN-γ and TGF-β in the spleno-
cytes culture supernatants were determined by a
sandwich immunoassay kit (BD Biosciences Pharmingen,
USA) in 96-well microplates performed according to the
manufacturer’s instructions. Absorbance was read at
450 nm on a microplate reader (Multiskan Ascent, Lab-
systems, Finland) within 30 min of stopping the reaction,
and cytokine concentrations were calculated from a
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ard. The results were expressed in pg/ml.
Data analysis
The results are expressed as the means ± S.D. Each ex-
periment was performed at least five times. One-way
ANOVA with Tukey’s post hoc test was performed using
GraphPad InStat version 3.0 for Windows 95, Graph-
Pad Software, San Diego, California, U.S.A. Values of
p < 0.05 were considered statistically significant.
Results
Flow cytometry analysis
Macrophage cell surface markers were used to evaluate
peritoneal cells, lymphocytes and dendritic spleen cells.
We observed that untreated tumor-bearing mice (group
T) presented an increase in the numbers of mature den-
dritic cells (CD11c+CD86+ and CD11c+MHCII+, p < 0.05
and p < 0.01, respectively) and CD4+CD25+ cells
(p < 0.01), accompanied by a reduction of total CD4+
and CD8+ cells (p < 0.001) when compared to control
healthy mice (group N). Pulchellin treatment (group P)
promoted an enhancement of adhesion (CD54) and cost-
imulatory (CD80) molecules expression in peritoneal
macrophages (p < 0.01), a significant reduction in the
number of CD4+CD25+ Treg cells (p < 0.01) and non-
significant reduction in the number of CD8 cells and
dendritic cells (p > 0.05) relative to the tumor control
group (T group) (Table 1).
Measurement of nitric oxide and cytokine production
In order to evaluate the immune response in mice that
received an intratumoral administration of pulchellin,
the production of nitric oxide and cytokines in the cell
culture supernatants of PEC and spleen cells was deter-
mined. Analysis of the PEC cells from pulchellin-treated
tumor-bearing mice revealed a higher production of NO
than that of the untreated tumor-bearing or healthyTable 1 Percentage of macrophages (peritoneum),
dendritic cells and lymphocytes (both from spleen) from







% CD11b+CD54+ 35.8 ± 2.6##*** 24.7 ± 2.2 23.1 ± 1.4
% CD11b+CD80+ 5.3 ± 1.3##** 1.1 ± 0.4 1.5 ± 0.2
% CD11c+MHCII+ 1.5 ± 0.1## 2.8 ± 0,5** 1.2 ± 0.1
% CD11c+CD86+ 0.2 ± 0.1# 0.4 ± 0.1* 0.2 ± 0.1
%CD3+CD4+ 9.0 ± 0.3*** 8.5 ± 0.2*** 17.6 ± 1.0
% CD4+CD25+ 0.1 ± 0.1## 1.0 ± 0.3** 0.1 ± 0.1
% CD3+CD8+ 2.6 ± 0.4*** 2.5 ± 0.4*** 6.7 ± 0.4
Data are represented as the mean ± SEM. Statistical significance was evaluated
by Tukey post hoc test. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. healthy
group; # p < 0.05 and ## p < 0.01 vs. tumor control group.mice (p < 0.05 and p < 0.01, respectively) after 24 h of
culture (Figure 1). The immune cells from pulchellin-
treated mice also produced statistically higher concen-
trations of TNF-α by PEC cells, and IL-4, IFN-γ and
IL-10 by splenocytes, and lower concentrations of IL-6
(PEC cells) and TGF-β (splenocytes), than the cells from
tumor control mice (Figures 2 and 3).
Discussion
In the last several years, researchers have demonstrated
the important role of the immune system in the control
or promotion of tumor development [7]. Pulchellin, a
type 2 RIP isolated from Abrus pulchellus tenuiflorus’
seeds, is a powerful toxin, structurally similar to abrin
and ricin. Although the anti-tumor activities and immu-
nomodulatory effects of abrin and ricin have been stud-
ied [8-10], there is no such published data for pulchellin.
In this study, we evaluated the production of some im-
mune mediators and the expression of surface markers
in different immune cells obtained from tumor-bearing
mice treated or not with pulchellin. We observed greater
production of IFN-γ by spleen cells from group P than
in those from group T. Since we couldn't detect IL-12
production by PECs from group P (data not shown), it
can be suggested that the increased IFN-γ production
found in this group is most likely the cause of the
enhanced expression of adhesion (CD54) and costimula-
tory (CD80) molecules and the production of TNF-α
and NO by macrophages [11]. In some cases, production
of IFN-γ can be triggered in the absence of IL-12 stimu-
lation, when there is enough antigen levels to keep aFigure 1 NO Synthesis by Peritoneal Macrophages. Adherent
cells (5x106 cells ml-1) were incubated for 24 h with RPMI-1640
culture medium. Cell-free supernatant was mixed with the Griess
reagent and the resulting reaction was read in a spectrophotometer.
P (tumor-bearing mice treated with pulchellin at 0.75 μg/kg of body
weight), T (tumor-bearing mice treated with saline solution) and N
(untreated healthy mice). One-way ANOVA with Tukey’s post test
was performed. ** p< 0.01 vs. N group; # p < 0.05 vs. T group.
Figure 2 IL-6 and TNF-α synthesis by PEC cells. For the cytokine immunoassays, adherent cells (5x106 cells ml-1) were incubated for
24 h with RPMI-1640 culture medium. Cell-free supernatant was assayed for IL-6 and TNF-α by ELISA according to the manufacturer’
instructions. P (tumor-bearing mice treated with pulchellin at 0.75 μg/kg of body weight), T (tumor-bearing mice treated with saline solution) and
N (untreated healthy mice). One-way ANOVA with Tukey’s post test was performed. ** p< 0.01, *** p < 0.001 vs. N group; ## p < 0.01 vs. T group.
Figure 3 IL-4, IL-10, IFN-γ and TGF-β synthesis by spleen cells. For the cytokine immunoassay, spleen cells (5x106 cells ml-1) were
incubated for 24 h with RPMI-1640 culture medium. Cell-free supernatant was assayed for IL-4, IL-10, IFN-γ and TGF-β by ELISA according to
the manufacturer’ instructions. P (tumor-bearing mice treated with pulchellin at 0.75 μg/kg of body weight), T (tumor-bearing mice treated with
saline solution) and N (untreated healthy mice). One-way ANOVA with Tukey’s post test was performed. * p< 0.05, ** p < 0.01 vs. N group; #
p < 0.05, ## p < 0.01 and ### p < 0.001 vs. T group.
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of the mitogen-activated Erk kinase protein, resulting in
IFN-γ-producing Th1 cells [12].
We also observed less activation of dendritic cells from
the spleens of group P mice than in mice from group T.
A group of researchers have already reported a similar
phenomenon when they treated immature human
monocyte-derived dendritic cells with ricin (type II RIP),
resulting in decreased expression of MHC II and CD86
in these cells. This may explain why pulchellin treatment
does not significantly change the percentage of CD4+
and CD8+ T cells in comparison to group T [13].
A reduction of CD4+CD25+ cells, as well as of TGF-β
and IL-6 production, was observed in group P compared
to group T. IL-6 is known to promote tumor growth by
upregulating anti-apoptotic and pro-angiogenic proteins
in tumor cells [14], and TGF-β is known to support
tumor progression by promoting cell invasion and dis-
semination to distant sites, enhancing angiogenesis and
mediating the immune evasion of tumor cells [15]. Be-
sides that, IL-6 is known to promote, together with
TGF- β, naive T cells differentiation into Th17 cells [16],
which are found in greater quantities in mice as breast
cancer progresses, reaching their highest levels at the
later stages of the disease [17]. CD4+CD25+ cells are nat-
urally occurrbca03ing Tregs and are recognized as a
major subset among the immune cells that are respon-
sible for peripheral immune self-tolerance. The accumu-
lation of CD4+CD25+ Tregs can result in tumor growth
through the suppression of anticancer immunity [18].
Consequently, the downregulation of these Tregs and
cytokines by pulchellin treatment might improve antitu-
mor immunity.
The increase in IL-10 and IL-4 release on group P ani-
mals may enhance the host immune response against
the tumor and aid in the control of tumor growth. IL-4
also plays a role in the immune response against various
tumors, including breast cancer, by inhibiting tumor
angiogenesis [19]. Meanwhile, IL-10 directly activates
and expands the antigen-specific IFN-γ-producing ef-
fector CD8 T cell pool inside the tumor, resulting in
higher IFN-γ levels which trigger the increased expres-
sion of intratumoral antigen presenting molecules [20].
Currently, there are several published data in which
RIPs are chemically linked to or genetically fused with
antibodies, growth factors, hormones and lectins for the
treatment of cancer. Based on the results of the present
work, pulchellin may be a candidate for further studies
as a drug that can produce immunotoxins with anti-
tumoral purpose.
Conclusions
Pulchellin exhibited several interesting activities, includ-
ing macrophage activation, the production of cytokinesknown to increase antitumor immunity and the reduc-
tion of pro-tumoral cytokines and CD4+CD25+ Treg
cells. These results provide a new perspective for cancer
treatment and suggest that pulchellin may be a candi-
date for the production of immunotoxins against breast
cancer.
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